CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms ...
CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic ...
New Recommendations for JAK Inhibitors, Anemia and Transplantation / American Society of Hematology (ASH), ASH 2026 ...
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification. Dr John Mascarenhas presents a patient case scenario of a ...
Beyond drug development, PharmaEssentia has expanded its global footprints. Since 2017, PharmaEssentia has established ...
Merck KGaA is to buy Silence Therapeutics plc for $1.3B cash at $20/ADS (130% premium). Click for a look at SLN and see why I ...
A recent study identified a distinct primary myelofibrosis (PMF) subgroup characterized by elevated hemoglobin at diagnosis. This variant, observed primarily in younger females, exhibits a higher ...
Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabilities ...
The Decades-Long Journey Behind the First Approved Telomerase Inhibitor / cancer, Cancer Drug Development, European Medicines ...
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results